Overview

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This study is a multi-center, open label, randomized controlled trial that main purpose of this study is to evaluate the differences of glucose control and weight loss between Beinaglutide and Dulaglutide in type 2 diabetes with overweight or or Obesity.

Phase:

Phase 4

Details

Lead Sponsor:

Second Xiangya Hospital of Central South University

Collaborators:

First Affiliated Hospital of Harbin Medical University
Guangdong Provincial People's Hospital
The First Affiliated Hospital of Henan University of Science and Technology

Treatments:

Dulaglutide
Glucagon
Glucagon-Like Peptide 1